342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia

BACKGROUND: Guidelines recommend use of tocilizumab (TCZ), an inhibitor of pro-inflammatory IL-6 signaling, for hospitalized patients with progressive severe or critical Coronavirus disease 2019 (COVID-19). The incidence of infectious complications following the use of TCZ for COVID-19 has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Warner, Adam, Abbas, Mujahed, Avner, Benjamin S, Flynn, Thomas E, Walroth, Todd A, Jagger, Brett W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690531/
http://dx.doi.org/10.1093/ofid/ofab466.543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690531/
http://dx.doi.org/10.1093/ofid/ofab466.543

Ejemplares similares